We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 3.25 | 26.53% | 15.50 | 12,615,904 | 15:48:16 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 15.00 | 16.00 | 17.35 | 14.50 | 14.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Business Services, Nec | 1.04M | -21.69M | -0.0832 | -1.86 | 40.39M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:32:43 | O | 434,425 | 15.6144 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 24/4/2024 | 10:32 | ALNC |  Angle shares jump on supplier agreement with with AstraZeneca |
| 24/4/2024 | 07:00 | UK RNS | Angle PLC New commercial agreement with AstraZeneca |
| 22/4/2024 | 16:52 | ALNC | IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide |
| 22/4/2024 | 07:00 | UK RNS | Angle PLC US and EU patents for innovative CellKeep™ slide |
| 08/4/2024 | 07:00 | UK RNS | Angle PLC Parsortix HER2 assay showcased at AACR 2024 |
| 22/3/2024 | 07:00 | UK RNS | Angle PLC Parsortix at European breast cancer conference |
| 22/1/2024 | 18:03 | ALNC | IN BRIEF: Angle highlights supportive data for DNA analysis tool |
| 22/1/2024 | 07:00 | RNSNON | Angle PLC Potential utility in precision oncology |
| 10/1/2024 | 12:57 | UKREG | Angle PLC Standard form for notification of major holdings |
| 04/1/2024 | 12:19 | ALNC | Angle shares soar following "breakthrough" cancer diagnostics results |
Angle (AGL) Share Charts1 Year Angle Chart |
|
1 Month Angle Chart |
Intraday Angle Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/4/2024 | 21:08 | ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY | 24,000 |
| 12/2/2024 | 09:42 | Angle PLC | 660 |
| 29/1/2024 | 20:18 | ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE." | 3,756 |
| 19/1/2024 | 11:27 | SHAREHOLDERS ACTION GROUP | 580 |
| 15/12/2023 | 08:29 | ANGLE PLC IT'S A SPOOF | 1,277 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:32:43 | 15.61 | 434,425 | 67,832.81 | O |
| 15:29:59 | 15.62 | 35,000 | 5,466.44 | O |
| 15:29:54 | 16.00 | 15,000 | 2,400.00 | O |
| 15:29:12 | 15.62 | 2,500 | 390.50 | O |
| 15:29:06 | 15.62 | 32,010 | 4,999.96 | O |
| Top Posts |
|---|
Posted at 24/4/2024 09:20 by Angle Daily Update Angle Plc is listed in the Business Services, Nec sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 12.25p.Angle currently has 260,580,547 shares in issue. The market capitalisation of Angle is £40,389,985. Angle has a price to earnings ratio (PE ratio) of -1.86. This morning AGL shares opened at 14.75p |
Posted at 24/4/2024 09:31 by sicilian_kan jelenko, hopefully they will have enough small customers, but I am going to await the financials before increasing my holding, as last year that was not the case. I don't think anyone is suggesting they will not be around. The issue is whether they need to dilute and if so the cost of that to us shareholders in terms of share price and dilution. At the moment, the share price is rightfully on the up. But if we get a revenue warning at any stage, we will see a sharp reversal. |
Posted at 21/4/2024 16:24 by 5oletrader Something to keep an eye on?- ROCHE snags postsurgery FDA nod for Alecensa, eyes even broader lung cancer use ROCHE isn't content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has now secured FDA approval in the post-surgical setting as it continues to test the drug in additional patient populations. With 1.5 BILLION Swiss francs ($1.65 BILLION) in 2023 sales, Alecensa is the top-selling med in the ALK inhibitor class, which also includes Takeda's Alunbrig and Pfizer's next-generation ALK/ROS1 inhibitor Lorbrena. ?Besides the adjuvant setting for resected tumors, ROCHE is also testing Alecensa in patients with locally advanced, unresectable, stage 3 NSCLC in the phase 3 HORIZON-01 trial.Https://www.fi |
Posted at 18/4/2024 07:42 by bones699 Agree with Ameretto years away from getting anywhere near full FDA approval to 'test' the majority of cancer groups without which there are no commercial prospects and by which time competitors would have over taken it and AGL would be on its second or even third successive cash placement with the share price trailing in the pennies with calls for Newland to resign!Just look at Astra Zenica they don't seem to be in any hurry to buy AGL at a mere £30m! |
Posted at 23/3/2024 17:40 by bones699 My nemesis fake Bones698 claimed he sold half his holding when the share price topped 40p on 4th January recently having been invested for a very long time yet didn't do similar when the share price touched 140p on 22nd May 2022...which tells me he never sold a single share, what a total liar, hence fake Bones698 spreading more lies! |
Posted at 29/2/2024 11:48 by stockgod2022 New to all of this, and commenting, so be gentle lol. I really fail to see how the share price is this low! It was a very similar price in 2016 and it baffles me how this "regulated" system seems really dodgy, and easily manipulated. I've been in on these for c8 years now and thought that once FDA approval was granted that we would see a consistent upward trend, but we have the complete opposite. Can anyone simply explain how the share price can be forced down this low, considering the great potential we have, along with the FDA accreditation, and also how this is allowed to happen. Tia |
Posted at 19/2/2024 12:14 by spa362 It is worth noting that in 4 out of the last 5 years, the AGL share price has been above 50p (sometimes considerably so). This is in line with broker forecasts and where the share is heading back to now that it has some ground breaking data on its side and increased exposure upcoming. Remains a good opportunity for both traders and long term holders alike. |
Posted at 07/2/2024 23:10 by timbo003 It was another informative meeting Waterloo, no new news (obviously) but quite a few new insights. The slide deck was more or less the same as that used at Proactive a couple of weeks ago. There were 5 companies presenting and Angle were on last (never a good place to be), we had about 10 minutes for Q&A and I have summarised some of the questions and responses belowI had a quick chat with the CFO before the meeting and asked him (in jest) whether Parsortix might soon gain a "by Royal appointment" accreditation. I speculated that HM's cancer could be bladder cancer and that if it was, Parsortix could be useful tool for tracking any cancer cell mutations. Ian opined that there was no way of knowing who was treating HM and what treatments was being employed, or whether the physicians were advocates of monitoring CTCs and Persortix in particular ☹️ Q&As Q: Looking at it from a business man’s perspective, I would be interesting in your comments on funding, briefly financial highlights, revenues for half year trebled to £2.2m, on the other hand you went through the thick end of £10m during that period of time and that is not an entirely comfortable position to read as a potential investor. A: That was planned investment, we raised £20m in June 2022, we are deploying the capital on specific activities, clinical studies, generating data that will get us customers. We are not just spending willy-nilly, this is actual planned expenditure And the medical industry, the nature of it is that You have to generate data to convince people particularly where you are doing a pioneering activity such as ourselves and particularly where people need to be convinced and the way to do that is through data and through partnerships and collaborations that costs money, you run a clinical study it takes a number of years, we have got the only FDA cleared product, that takes a lot of money, most of our competitors cannot do that, so if you want a traditional organisation, we are not a dividend, we are not a safe stock, but we are pioneering we are developing and we are deploying the capital that we raised, now in terms of what that means going forward, we needed to give a trading update back in november, that was revenues for the full year was only £2.2m, yes it is modest at this stage, the money we have got will take us out to Q2 2025, we are aiming to be cash flow break even by end of 2025, so we do have a gap in terms of getting through to cash flow breakeven, we are seeking to fill that with either accelerating revenues further if we can, getting milestone payments or doing deals with large strategics or corporates, but we are doing that on a shoe string compared to our American cousins, but the nature of the industry we are in means we have to deploy capital to get that leadership position, we are the only company with FDA clearance, we’ve got best in class results from the studies in ovarian 95.4% area under the curve all those things cost money, they don’t happen by not spending money. Q: Can I draw from that if I invested I could expect a rights issue somewhere in early 2025? A: As I’ve just explained, we are seeking to accelerate revenue growth or we are seeking to get milestone payments from strategic partners which would mean that we don’t have to do a capital raise. Historically we have done a capital raise every year because we were much earlier in the process to commercialisation, so you know, that is part of being a listed company, you know, you can raise capital, we are very tightly focusing our spend, we are a platform technology but we are only working on a limited number of cancers, we don’t need to raise immediately, clearly we will need capital to fill that gap, whether that is from a partner or from the market or see when we get to that point. Q: You mentioned the NCCN guidelines for secondary biopsies in metastatic breast cancer in the US, what % of patients undergo a secondary biopsy and what % of patients have a CTC biopsy instead? A: For the current standard of care in the US, the guidelines require a biopsy where it is possible, in reality just under 50% get a biopsy, the remainder are either too sick for the operation or they elect not to have it, they don’t want to go through another operation, or there is not enough material available so if it is a lung biopsy they cannot get enough out, or if it is in the bones, obviously if it is in the brain it is too dangerous and your question was what % of patients have a CTC biopsy? Zero, this is what we are working to try and achieve, a groundswell change in the way medical scientists are operating. Q: Do you suppose that some of the patients die from the result of the biopsy? A: Yes some of them do, and also some die from being given drugs which have side effects and no benefit, even more of them die from that. Q: There has been an incredibly long accumulation of data that should create visibility for the world for companies to see the potential, why is this not stabilising the share price? Please explain to me the correlation? A: We cannot control the supply and demand in the stock market. There have been massive movements of capital away from growth stocks, pushed down by redemptions from funds for 28 months in a row where people have taken their money out of investment funds, this is not an Angle specific thing, every single med-tech stock pretty much in the world and certainly in the UK is heavily down, but I couldn’t agree with you more, that is why we do these kind of meetings, it is to get more interest, more understanding, When you are trying to do something new, where people don’t know about it and we can sit in an ivory tower and assume they know about it, but they don’t, so we have to go out and spread that message. Q: Is there an alternative method of funding that mitigates the share price instability. A: If we go back to the slide I was showing, just one customer Eisai, Eisai currently has 80 clinical trials with 60K patients, a base price $4.6K for a tube of blood, we have discounted that to $2.5K for the pilot, each patient has a minimum of three time points so just this one company 60K patients, three time points at $4.6K each, there is a huge opportunity for building revenue. It took us the best part of a year to close the negotiation with Eisai, including six months waiting for their ???? but now we are in and last week I went to New York and met their people and talked to them about this project and other potential projects and they understand it, they want to see the data from the pilot so we cannot get ahead of ourselves, we have to show them that we have good data, but this is just one company. They are probably 20th on the list of top 20 companies they are not the biggest, there are other big companies and they can all benefit themselves financially and obviously we can too, so my hope is that by working with these kind of companies, they will take us the whole way to the market for a companion diagnostic, so they will pay for us to obtain extended FDA clearance, they will pay for marketing, they will probably be the customer who pays for it. So if you are selling a drug for $100K, would you pay for a blood test for a couple of thousand? Of course you would if you can get $100K for selling the drug, so there are plenty of opportunities for us to just do a companion diagnostic paid for by them. |
Posted at 28/1/2024 09:10 by bones699 So let's talk about financial fundamentals here shall we rather than day dreaming chasing vanishing rainbows over the horizon. 🌈 🤔.Now Parsortix has been cleared for nearly two years and there is around 24 main cancer types of which only one has been approved by the FDA for testing breast cancer using the Parsortix machine. So here is the conundrum not only has AGL generated virtually no sales revenues in two years despite having approval for breast cancer treatment but to generate sales it is unwilling to complete the testing required for the remaining 23 cancer types expecting the third party labs to do this themselves. Well it doesn't take a rocket scientist to figure out that to date LabCorp and Quest Diagnostics the two USA leading lab company's has shown next to no interest in buying Parsortix machines due no doubt to the severe limitation in cancer testing. Hence Newlands claim at the recent Investor Meet that third party labs are likely to take on Parsortix and seek their own accreditation because that is exactly what he was alluding too appear unfounded! As to date non of the big USA lab chains have done what Newland claimed they would do in nearly two years since FDA clearance!... We can now see that the financial fundamentals are beginning to fall apart, low cash balances c.£12m at best, a high monthly cash burn rate over £1.4m and Newland claiming that an additional £6m revenues will occur out of apparently thin air only reference at the Investor Meet by their CFO looking quite twitcher I might add when asked about the cash runway was funding would be from 'strategic opportunities' and 'project milestones' whatever that was meant to mean before alluding to tapping the market as in the past, just gave the game away don't you think! So there we have the crux of the matter a business running out of both time and money before the next eventual cash raise. Meanwhile the market has now cottoned on to Newlands tricks ramping RNS releases all of which lack financials and timelines with the seeming sole objective to keep the share price up ahead of a potential cash raise to mitigate the size and scale of yet another damaging £20m share issuance, to chuck onto the pile of burnt investor cash over £130m to date, and at what share price 12p or much less by the look of things.. Meanwhile other competitors are entering the market space and closer to full FDA approval than AGL while 'BIG PHARMA' could have picked AGL up for under 10p and show no interest, no surprises there then! AGL should carry a government health warning that these 🌈's are never free and can and do fade over time! |
Posted at 23/1/2024 08:18 by bones699 Yes I am making lots of money here and no I am not miserable. I also lie alot like claiming that the AGL share price would hit 40p..why not 50p, 60p, or eben just 30p always easy to lie after the event ain't it bones. 😉 |
Posted at 22/1/2024 21:53 by bones699 Yet the share price continues to dive why is that?...Why does Newland allow these ramping RNS's to be released which contain nothing in terms of financials. What's the rational did we learn anything new today...no we didn't..so what was the real purpose are we on the way for an imminent cash raise because the projected £6m revenues that he himself communicated to the market are at risk, more so, aren't going to happen, why because they were never likely to happen and the CEO is playing for time.. With remaining cash balance probably only £12m at best in December and a high monthly cash burn rate over £1.5m is he now in a hole..running out of both cash and time... Audited year end financials can't be signed off unless there is a minimum 12 months cash flow to meet the 'Going Concern' requirements..is this the issue, AGL, is running out of cash faster than expected and an imminent cash raise is on the cards, hence all these bizarre rampy RNS's with little substance to them..to try and prop the share price up before the inevitable cash raise and subsequent and inevitable shareholder dilution. It seems the market thinks the same judging by the share price reaction!..all the Day Traders have vanished and current investors appear anxious judging by the snide comments on this BB and with very good reasons I would say! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
